{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T21:59:31Z","timestamp":1768687171630,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T00:00:00Z","timestamp":1193875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1016\/j.autrev.2007.06.002","type":"journal-article","created":{"date-parts":[[2007,7,19]],"date-time":"2007-07-19T07:16:11Z","timestamp":1184829371000},"page":"46-51","source":"Crossref","is-referenced-by-count":33,"title":["Insights into atherosclerosis therapy in antiphospholipid syndrome"],"prefix":"10.1016","volume":"7","author":[{"given":"Cristina C.","family":"Belizna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Richard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Thuillez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"L\u00e9vesque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yehuda","family":"Shoenfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2007.06.002_bib1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jaut.2007.02.009","article-title":"Antiphospholipid antibodies: lessons from the bench","volume":"28","author":"Koike","year":"2007","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2007.06.002_bib2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S1568-9972(02)00144-1","article-title":"Antiphospholipid antibodies: pathogenic mechanisms","volume":"2","author":"Espinosa","year":"2003","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2007.06.002_bib3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.autrev.2006.03.001","article-title":"Interaction of giant phospholipid vesicles containing cardiolipin and cholesterol with beta2-glycoprotein-I and anti-beta2-glycoprotein-I antibodies","volume":"6","author":"Ambrozic","year":"2006","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2007.06.002_bib4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jaut.2005.10.002","article-title":"Characterization of monoclonal anti-beta2-glycoprotein-I and anti-prothrombin antibody fragments generated by phage display from a patient with primary antiphospholipid syndrome","volume":"26","author":"Languren","year":"2006","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2007.06.002_bib5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.autrev.2006.06.007","article-title":"Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors","volume":"6","author":"Bucciarelli","year":"2006","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2007.06.002_bib6","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/oxfordjournals.aje.a009122","article-title":"Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study","volume":"145","author":"Manzi","year":"1997","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.autrev.2007.06.002_bib7","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.autrev.2005.12.006","article-title":"Inflammation: a pivotal link between autoimmune diseases and atherosclerosis","volume":"5","author":"Abou-Raya","year":"2006","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2007.06.002_bib8","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1177\/096120339800700229","article-title":"Antiphospholipid antibodies and myocardial infarction","volume":"7","author":"Vaarala","year":"1998","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2007.06.002_bib9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jaut.2007.02.004","article-title":"The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia","volume":"28","author":"Hahn","year":"2007","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2007.06.002_bib10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.autrev.2005.06.005","article-title":"Accelerated atherosclerosis, immune response and autoimmune rheumatic diseases","volume":"5","author":"Jara","year":"2006","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2007.06.002_bib11","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jaut.2007.02.013","article-title":"Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process?","volume":"28","author":"Cavazzana","year":"2007","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2007.06.002_bib12","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/0140-6736(93)91213-6","article-title":"Crossreaction between antibodies to oxidized low-density lipoprotein and to cardiolipin in systemic lupus erythematosus","volume":"341","author":"Vaarala","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2007.06.002_bib13","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jaut.2006.09.007","article-title":"Patients with atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA autoantibodies that preferentially target domain 4 of beta2-GPI","volume":"27","author":"Iverson","year":"2006","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2007.06.002_bib14","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11926-003-0029-1","article-title":"Oxidative stress in systemic lupus erythematosus and antiphospholipid syndrome: a gateway to atherosclerosis","volume":"5","author":"Alves","year":"2003","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2007.06.002_bib15","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1161\/01.CIR.98.11.1108","article-title":"Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with beta2-glycoprotein I","volume":"98","author":"George","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2007.06.002_bib16","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1002\/art.11255","article-title":"Reduction of atherosclerosis in low-density lipoprotein receptor-deficient mice by passive administration of antiphospholipid antibody","volume":"48","author":"Nicolo","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2007.06.002_bib17","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cardiores.2004.01.028","article-title":"Suppression of early atherosclerosis in LDL-receptor deficient mice by oral tolerance with beta 2-glycoprotein I","volume":"62","author":"George","year":"2004","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.autrev.2007.06.002_bib18","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1002\/1529-0131(200112)44:12<2870::AID-ART475>3.0.CO;2-Y","article-title":"Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype","volume":"44","author":"Meroni","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2007.06.002_bib19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1160\/TH06-06-0340","article-title":"Immunization of LDL receptor-deficient mice with \u03b2 (2)-glycoprotein 1 or human serum albumin induces a more inflammatory phenotype in atherosclerotic plaques","volume":"97","author":"Dunoyer-Geindre","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.autrev.2007.06.002_bib20","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/j.1538-7836.2004.00896.x","article-title":"Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells","volume":"2","author":"Ferrara","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2007.06.002_bib21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1385\/IR:25:3:271","article-title":"Antiinflammatory and immunomodulatory properties of statins","volume":"25","author":"Shovman","year":"2002","journal-title":"Immunol Res"},{"key":"10.1016\/j.autrev.2007.06.002_bib22","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1161\/01.CIR.97.12.1129","article-title":"Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors","volume":"97","author":"Laufs","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2007.06.002_bib23","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1002\/art.11449","article-title":"Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model","volume":"48","author":"Ferrara","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2007.06.002_bib24","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.4049\/jimmunol.177.5.3028","article-title":"Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model","volume":"177","author":"Aprahamian","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2007.06.002_bib25","first-page":"S2001","article-title":"Atorvastatin reduces MHC class II expression and ameliorates autoimmunity in the NZB\/W mouse model of lupus","volume":"48","author":"Lawman","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2007.06.002_bib26","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1191\/0961203303lu429oa","article-title":"Therapy with statins in patients with refractory rheumatic diseases: a preliminary study","volume":"12","author":"Abud-Mendoza","year":"2003","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2007.06.002_bib27","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1160\/TH04-05-0297","article-title":"Fluvastatin increases the expression of adhesion molecules, monocyte chemoattractant protein-1 and tissue factor in HUVEC stimulated by patient IgG fractions containing antiphospholipid antibodies","volume":"93","author":"Dunoyer-Geindre","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.autrev.2007.06.002_bib28","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/j.1538-7836.2004.00801.x","article-title":"Aspirin inhibits endothelial cell activation induced by antiphospholipid antibodies","volume":"2","author":"Dunoyer-Geindre","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.autrev.2007.06.002_bib29","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1161\/01.ATV.0000083296.57581.AE","article-title":"Aspirin protects endothelial cells from oxidant damage via the nitric oxide-cGMP pathway","volume":"23","author":"Grosser","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.autrev.2007.06.002_bib30","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1096\/fj.00-0843fje","article-title":"Aspirin inhibits NF-kappaB and protects from angiotensin II-induced organ damage","volume":"15","author":"Muller","year":"2001","journal-title":"FASEB J"},{"key":"10.1016\/j.autrev.2007.06.002_bib31","first-page":"S17","article-title":"Mortality and malignancy in the multi-ethnic Birmingham Lupus Cohort\u2014aspirin use is beneficial and non-Caucasian origin is not associated with a poor outcome","volume":"41","author":"Leung","year":"2002","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2007.06.002_bib32","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1161\/CIRCULATIONAHA.105.590083","article-title":"Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase","volume":"113","author":"Baldus","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2007.06.002_bib33","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1161\/CIRCULATIONAHA.106.631457","article-title":"Heparin displaces interferon-gamma-inducible chemokines (IP-10, I-TAC, and Mig) sequestered in the vasculature and inhibits the transendothelial migration and arterial recruitment of T cells","volume":"114","author":"Ranjbaran","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2007.06.002_bib34","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2174\/138955706778195180","article-title":"Structural requirements of heparin and related molecules to exert a multitude of anti-inflammatory activities","volume":"6","author":"Ludwig","year":"2006","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.autrev.2007.06.002_bib35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-2007-995820","article-title":"The anti-inflammatory properties of antithrombin III: new therapeutic implications","volume":"24","author":"Okajima","year":"1998","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.autrev.2007.06.002_bib36","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa035471","article-title":"Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus","volume":"349","author":"Roman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2007.06.002_bib37","doi-asserted-by":"crossref","first-page":"R151","DOI":"10.1186\/ar2045","article-title":"Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study","volume":"8","author":"van Halm","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2007.06.002_bib38","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1136\/ard.62.11.1071","article-title":"Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus","volume":"62","author":"Doria","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2007.06.002_bib39","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.cardiores.2005.09.018","article-title":"Mycophenolate mofetil (MMF): firing at the atherosclerotic plaque from different angles?","volume":"69","author":"van Leuven","year":"2006","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.autrev.2007.06.002_bib40","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1006\/jsre.2000.5919","article-title":"Mycophenolate mofetil treatment reduces atherosclerosis in the cholesterol-fed rabbit","volume":"91","author":"Greenstein","year":"2000","journal-title":"J Surg Res"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997207001127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997207001127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T11:43:23Z","timestamp":1544010203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997207001127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["S1568997207001127"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2007.06.002","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2007,11]]}}}